WallStSmart

Abbott Laboratories (ABT)vsHaemonetics Corporation (HAE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 3346% more annual revenue ($46.59B vs $1.35B). ABT leads profitability with a 11.7% profit margin vs 7.1%. HAE appears more attractively valued with a PEG of 1.63. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

HAE

Hold

50

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 6.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.51
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.8%)

Margin of Safety

-37.8%

Fair Value

$74.19

Current Price

$102.61

$28.42 premium

UndervaluedFair: $74.19Overvalued
HAEUndervalued (+34.3%)

Margin of Safety

+34.3%

Fair Value

$87.46

Current Price

$108.40

$20.94 discount

UndervaluedFair: $87.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

HAE0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

HAE4 concerns · Avg: 3.8/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Altman Z-ScoreHealth
1.514/10

Distress zone — elevated risk

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : HAE

HAE has a balanced fundamental profile.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : HAE

The primary concerns for HAE are PEG Ratio, EPS Growth, Altman Z-Score. A P/E of 49.7x leaves little room for execution misses.

Key Dynamics to Monitor

ABT carries more volatility with a beta of 0.59 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (54/100 vs 50/100) and 13.0% revenue growth. HAE offers better value entry with a 34.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Haemonetics Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?